World Journal of Gastroenterology
Cure8 research brief
Why This Matters
The study suggests that using infliximab as first-line therapy (rather than IV corticosteroids) may produce more durable remission and reduce long-term colectomy risk in moderate-to-severe ulcerative colitis.
Who Should Pay Attention
Adults with moderate-to-severe ulcerative colitis, clinicians who manage IBD, and patients considering biologic therapy versus steroid-based induction.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This real-world study enrolled 152 patients (139 with complete follow-up) and followed them for at least 24 months. The IFX group received standard induction (5 mg/kg at weeks 0, 2, 6) and 8-week maintenance; the IVCS group received methylprednisolone or hydrocortisone per protocol.
By week 144, IFX-treated patients had higher remission rates (clinical, endoscopic, histologic) and fewer colectomies compared with IVCS. Adverse events were reported as comparable overall in the manuscript.
Clinical context: The findings support considering early biologic therapy for selected high-risk patients with moderate-to-severe UC, but treatment choice should remain individualized and discussed with a gastroenterologist. This brief summarizes the study abstract and does not replace reading the full paper or medical advice.
Keep In Mind
This summary is grounded in the article abstract (multicenter prospective cohort, follow-up to 144 weeks). As an observational cohort rather than a randomized trial, residual confounding is possible; individual treatment decisions depend on patient-specific factors and clinician judgment.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationWorld Journal of Gastroenterology
PublisherBaishideng Publishing Group Inc.
AuthorsHossam M Elsaadany, Basem Abd El-Hamid, Emad A Elewesy +6 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 14, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
Upadacitinib for Acute Severe Ulcerative Colitis: Real-World Tertiary Care Outcomes.
Hospitalized patients with acute severe ulcerative colitis often need rescue therapy to avoid colectomy.
Effectiveness and safety of tacrolimus versus infliximab as rescue therapy for intravenous corticosteroid-refractory acute severe ulcerative colitis: a multicenter cohort study.
This study directly compares two rescue medications used when intravenous steroids fail in acute severe ulcerative colitis, reporting similar short-term remission and safety but a slower early response with tacrolimus —...